Epitalon Nasal Spray: Evidence, Formulation and Research Questions

Epitalon nasal spray means the nasal administration of Epitalon (Epithalon; AEDG, Ala-Glu-Asp-Gly) via the nasal cavity, although published evidence is largely limited to rat studies rather than controlled human trials. Nasal Epitalon induced measurable neuronal and pineal responses in animals, but human bioavailability, optimal formulation, delivered dose and route-specific safety remain undetermined. [1–3]

Interest in searching for the term Epitalon nasal spray is often based on the assumption that the nasal route is already well characterised clinically. The scientific literature does not support this.

The strongest direct evidence comes from a small group of preclinical studies in which intranasal Epitalon was administered to rats. These experiments analysed the neural activity of the cerebral cortex and pineal gland responses under stress. They show that intranasal exposure can induce measurable biological effects in an animal model, but they do not establish human pharmacokinetics, absolute bioavailability, brain concentration, clinical efficacy, or an evidence-based protocol for spray use. [1–3]

The nasal spray also comprises two distinct scientific elements: the active substance and the delivery system. Even if two products nominally contain the same amount of Epitalon, they can deliver different amounts to the nasal mucosa because they may differ in concentration, actuation volume, droplet size, spray pattern, formulation viscosity, pH, preservatives and actuator design. FDA guidance on nasal products takes precisely this relationship between formulation and device into account.

What is Epitalon Nasal Spray?

Epitalon nasal spray is a formulation designed to deliver the tetrapeptide AEDG via the nasal cavity rather than through injection or ingestion. Published research on Epitalon has used the intranasal route in rats, but has not demonstrated a standardised spray formulation for humans, a clinically validated dose per actuation, or established nasal bioavailability. [1–3]

The nasal administration term means the placement of a substance in the nasal cavity, where it can contact the nasal mucosa.

The nasal mucosa is highly vascularised, making it an attractive route for local or systemic drug delivery. For certain compounds, researchers are also investigating the possibility of facilitating access to the central nervous system via pathways associated with the olfactory region and the trigeminal nerve.

That was precisely the starting point of classical neurophysiological research on Epitalon.

Sibarov and co-workers described the intranasal route as a non-invasive pathway chosen to facilitate the delivery of Epitalon to the central nervous system. In urethane-anaesthetised male Wistar rats, extracellular cortical neuronal activity was recorded following intranasal exposure to Epitalon. [1]

A related Russian-language publication by the same research group also described the modulation of cerebral cortex neuronal activity following intranasal administration of Epitalon. [2]

In another rat study, intranasal Epitalon was used during the analysis of C-Fos expression in the pineal gland and structural changes induced by osmotic stress. [3]

These experiments confirm that nasal Epitalon was investigated experimentally.

However, they do not prove that commercially available nasal sprays replicate the same formulation, concentration, deposition pattern, systemic exposure or central nervous system exposure.

A broader comparison of administration routes can be found in the article Epitalon Injection and Administration Routes in Research.

Has Nasal Epitalon Been Researched in Humans?

There are no robust controlled human studies establishing the pharmacokinetics, bioavailability, clinical efficacy, or safety of intranasal Epitalon. Direct literature regarding this route mainly involves rat studies, therefore animal results should not be interpreted as evidence of predictable systemic or central nervous system exposure in humans. [1–3]

This is the most important limitation of the evidence.

Published research on rats shows biological responses following nasal exposure, but does not answer questions relevant to human application.

They do not establish, among other things:

• what fraction of the nasal dose is absorbed into the systemic circulation;
• what concentration of intact AEDG is reached in human plasma;
• what is the time to reach maximum concentration;
• what part remains in the nasal cavity and what part enters the alimentary tract after swallowing;
• what concentrations are achieved in the brain or cerebrospinal fluid;
• what is the pharmacokinetics after repeated administration;
• how is nasal mucosal exposure tolerated;
• are there clinical effects regarding sleep, cognitive function, longevity, or the endocrine system.

A 2007 study of the rat cerebral cortex recorded changes in neuronal activity shortly after intranasal administration. [1]

This was an acute electrophysiological endpoint in anaesthetised rats, rather than evidence of therapeutic benefit or quantitatively determined delivery to the human brain.

Similarly, an experiment concerning pineal stress demonstrated changes in C-Fos expression and a partial reduction in stress-related structural changes in the pineal tissue of rats. [3]

This is also preclinical physiology.

Statements such as „Epitalon nasal spray crosses the blood–brain barrier in humans”, „nasal Epitalon is rapidly absorbed in humans”, or „nasal Epitalon has a higher bioavailability than injection” therefore require direct pharmacokinetic data in humans, which are currently lacking.

How does intranasal administration differ from injection?

Nasal and injectable Epitalon differ in the way the peptide reaches the tissues. Nasal administration depends on formulation deposition and absorption through the nasal mucosa, whereas subcutaneous or intramuscular injection bypasses the barriers of the nose and the gastrointestinal tract. However, there is no robust human study directly comparing the pharmacokinetics or efficacy of these routes.

Injection and nasal administration are fundamentally different exposure systems.

Injection

Subcutaneous administration has a significantly larger historical research base regarding Epitalon, particularly in rodent experiments concerning ageing, lifespan and neoplasms.

Injection bypasses both gastrointestinal digestion and the nasal mucosa. The administered peptide still needs to be absorbed from the injection site, but the amount does not depend on spray plume geometry or nasal deposition.

Nasal spray

The nasal spray must first deposit the formulation in the appropriate region of the nasal cavity.

Several processes may subsequently occur. The material may remain locally on the mucous membrane, be absorbed into the systemic circulation, be removed by mucociliary clearance, be swallowed and enter the gastrointestinal tract, or potentially interact with pathways leading towards the central nervous system.

The proportion of material following each of these paths depends on the formulation and the characteristics of the device.

Broader research on nasal products shows that the spray angle, droplet size, formulation properties and device geometry can significantly alter the deposition site of the material within the nasal cavity. [4]

The FDA also treats the nasal spray formulation and pump as interdependent elements when assessing product quality and bioavailability or bioequivalence.

Therefore, the nominal statement „1 mg intranasally” cannot be automatically compared with „1 mg by injection”, as if both routes led to identical biological exposure.

No validated conversion factor between these routes in humans has been established for Epitalon.

What Determines the Amount of Epitalon Delivered by the Spray?

The amount delivered by an Epitalon nasal spray depends on the peptide concentration, the volume of liquid released per actuation, the repeatability of the pump's operation, its priming state, the viscosity of the formulation, the spray pattern, the droplet size, and the design of the device. Therefore, the concentration in the bottle alone does not determine what amount of peptide reaches the nasal mucosa in a single spray.

One spray means a single actuation of the pump mechanism.

In the case of a metered nasal product, the theoretical amount of peptide released per actuation depends on two fundamental values: the concentration of the peptide in the solution and the volume of liquid expelled by the pump.

However, the actual performance of the product is more complex than simple arithmetic.

FDA guidance on nasal sprays indicates many quality attributes that can affect the delivered dose and product performance, including pump parameters, spray content uniformity, spray pattern, plume geometry, droplet size distribution, formulation composition, and container-closure system properties.

Independent studies on nasal formulation deposition also show that droplet size, spray characteristics, and the angle of application can influence the site of deposition of the material in the nasal cavity. [4]

In the case of a nasal product with Epitalon, a scientifically useful specification should therefore contain more information than just the total amount of peptide in the bottle.

Key parameters include:

• total peptide concentration;
• verified delivered volume per actuation;
• dose uniformity;
• the number of validated sprays;
• pump preparation requirements;
• droplet size distribution;
• spray pattern and jet geometry;
• pH and viscosity of the formulation;
• peptide stability throughout the declared period of use.

In the absence of such data, statements such as „each spray delivers exactly X micrograms” should be regarded as product-specific claims made by the manufacturer, rather than as an independently established pharmacological property of Epitalon.

What Are the Challenges of Nasal Formulation Stability?

The nasal formulation of Epitalon must maintain the peptide's identity, concentration, chemical stability, microbiological quality, and consistent spray performance during storage and repeated use. Aqueous formulations may be subject to degradation, contamination, adsorption, aggregation, pH changes, the influence of preservatives, and changes in pump performance, while stability data for nasal Epitalon remain limited.

A nasal spray is more complex than simply dissolving the peptide in water and putting the solution in a pump bottle.

The peptide must maintain its chemical integrity throughout the stated storage and usage period.

The formulation must also deliver a repeatable quantity with each actuation.

Several categories of stability matter.

Chemical Stability

The concentration of AEDG may theoretically change as a result of degradation or interactions with formulation components.

Current peer-reviewed literature regarding Epitalon does not specify a universal period of aqueous stability for the nasal formulation.

Therefore, statements such as „Epitalon nasal spray remains stable for 30 days” require analytical testing of a specific product rather than extrapolation from general peptide storage principles.

Microbiological Stability

Opening and starting the device repeatedly may create a potential route for contamination.

A multi-dose nasal product may therefore require a preservative system or a packaging design capable of maintaining microbiological quality for the stated shelf life.

A preservative can limit the growth of microorganisms, but it does not automatically prevent peptide degradation.

Physical Stability

Aggregation, precipitation, adsorption to the surface of the bottle or pump, and changes in viscosity can alter the amount delivered upon application.

FDA guidelines on nasal sprays emphasise the importance of the container-closure system, pump performance, particle or droplet size distribution, and dose uniformity as elements of product quality.

Device Stability

The pump itself can change its performance over time.

Changes to the applicator function can affect the volume, spray pattern or deposition, even if the peptide concentration in the bottle remains unchanged.

Therefore, formulation stability and device performance stability should be evaluated together.

Broader stability guidelines are discussed in the article Epitalon Reconstitution, Storage and Stability for Laboratory Research.

Is N-Acetyl Epitalon Spray the Same as Epitalon?

No. N-acetyl Epitalon is chemically modified at the N-terminal end and should not be regarded as identical to unmodified Epitalon, i.e. AEDG. PubChem identifies N-acetyl Epitalon as Ac-Ala-Glu-Asp-Gly-OH, with a different molecular formula and molecular weight, and clinical or pharmacokinetic data relating to one form cannot automatically be applied to the other.

Unmodified Epitalon is normally described as:

H-Ala-Glu-Asp-Gly-OH

N-acetyl Epitalon is described as:

Ac-Ala-Glu-Asp-Gly-OH

This acetyl group at the N-terminal end alters the molecule.

PubChem lists the molecular formula for N-acetyl Epitalon as C16H24N4O10 and its molecular mass as approximately 432.38 g/mol. The FDA’s Substance Register also lists N-acetyl Epitalon as a separate, verified chemical substance with the UNII identifier UXR7AF6R4F.

This distinction matters because chemical modification can affect properties such as susceptibility to enzymes, charge distribution, solubility, receptor interactions, membrane transport, or pharmacokinetics.

Such potential effects, however, must be measured.

The fact that N-acetylation can theoretically affect stability does not prove that N-acetyl Epitalon has better nasal bioavailability, a longer half-life, greater penetration into the central nervous system or greater efficacy.

An additional terminological problem arises in internet products: N-acetyl Epitalon and N-acetyl Epitalon amidate are sometimes presented as if they were interchangeable.

They do not have to be the same structure.

N-acetyl Epitalon in free acid form is Ac-AEDG-OH, whereas the amidated derivative additionally modifies the C-terminal end to Ac-AEDG-NH2. Therefore, the latter form is a doubly modified analogue.

The distinction should be confirmed on the basis of analytical documentation, and not just the product name.

Most importantly, classic literature regarding Epitalon — telomerase, melatonin, animal lifespans, and intranasal studies in rats — used unmodified AEDG rather than N-acetyl Epitalon.

Targeted searches identified chemical registries for N-acetyl Epitalon, but found no comparable peer-reviewed human pharmacokinetic research base or clinical studies on the nasal acetylated form that would confirm the reproduction of the biological effects of unmodified Epitalon.

What Evidence is Needed for Nasal Spray Comparison?

A reliable comparison of Epitalon nasal sprays requires data on chemical identity, concentration, purity, formulation, pump performance, delivered dose uniformity, droplet characteristics, stability, microbiological quality, and ideally also pharmacokinetics. Simply comparing the number of milligrams in the bottle or the declared number of sprays does not confirm equivalent exposure or product performance quality.

Two sprays labelled as „Epitalon” can differ significantly even with the same total peptide mass.

A useful scientific comparison should above all confirm that both products contain the same molecule.

This is of particular importance when one product contains unmodified Epitalon and the other N-acetyl Epitalon or an amidated derivative.

The next level is analytical quality. Relevant data would include:

• the peptide sequence and the chemical form;
• chromatographic purity;
• identity confirmation using mass spectrometry;
• declaration of actual peptide content;
• impurities and degradation products;
• formulation pH and excipients;
• microbiological testing, if required;
• validated delivered volume per actuation;
• dose uniformity;
• droplet size distribution;
• spray pattern and jet geometry;
• stability throughout the declared shelf life;
• documentation concerning a specific batch.

FDA guidelines on nasal products show why this level of characterisation is important: in the case of sprays, the formulation and the device jointly affect the delivered dose and the functioning of the product.

Even more data is needed to compare the bioavailability.

Researchers would need to conduct pharmacokinetic studies measuring intact peptide concentrations following administration, ideally alongside concentration–time curves and a direct comparison of the formulations under controlled conditions.

Controlled human studies would then be needed to compare clinical efficacy.

Without these layers of evidence, claims such as „product A is stronger because it contains more milligrams”, „the N-acetyl spray has greater bioavailability” or „one actuation of one brand equates to the same exposure as one actuation of another brand” are not scientifically established.

What the Evidence Regarding Nasal Epitalon Actually Shows

The overall state of the evidence is therefore best described as preclinical proof of concept for the intranasal route, rather than validated human intranasal pharmacology.

Frequently Asked Questions About Epitalon Nasal Spray

Has Epitalon Nasal Spray Been Researched?

Yes, but mainly in rats rather than humans. In published studies, intranasal Epitalon was used to analyse the activity of cerebral cortex neurones and the pineal gland's response to stress. These experiments demonstrate biological activity following intranasal exposure in animals, but do not establish human bioavailability, clinical efficacy or a validated spray protocol. [1–3]

Does Epitalon Nasal Spray Cross the Blood–Brain Barrier?

Researchers in rats chose the intranasal route partly because they considered it a potential method for delivery to the central nervous system, and they observed rapid responses of cerebral cortex neurones. However, these experiments did not directly measure the passage of intact Epitalon across the blood-brain barrier in humans, therefore definitive claims regarding delivery to the human brain are not substantiated.

How much Epitalon does one spray deliver?

This cannot be determined from the size of the bottle alone. The amount delivered depends on the peptide concentration and the actual volume dispensed by the pump per actuation, while the formulation and device performance may further affect dose uniformity. A reliable value per spray therefore requires validated data for the specific product.

Does Nasal Epitalon Have Higher Bioavailability Than Oral?

This has not been demonstrated in a controlled human pharmacokinetic study of Epitalon. Nasal administration bypasses direct exposure to a significant portion of the gastrointestinal tract, but the amount absorbed through the nasal mucosa remains unknown; therefore, an evidence-based percentage or the superiority of this route cannot currently be stated.

Is Nasal Epitalon Better than Epitalon Injection?

There is no controlled evidence in humans confirming the superiority of nasal Epitalon over injection in terms of bioavailability, efficacy, safety, or clinical outcomes taking into account user convenience. Injection has a larger historical base of animal studies, whereas nasal Epitalon has been studied mainly in rat neurophysiology and pineal gland experiments.

Is N-Acetyl Epitalon the Same Peptide as Epitalon?

No. Unmodified Epitalon is AEDG with an unmodified N-terminal end, whereas N-acetyl Epitalon contains an additional acetyl group at that end. PubChem and FDA substance registries treat N-acetyl Epitalon as a distinct chemical entity, therefore data concerning unmodified Epitalon cannot be automatically attributed to the acetylated form.

Is N-Acetyl Epitalon Amidate the Same as N-Acetyl Epitalon?

Not necessarily. N-acetyl Epitalon in the free acid form is presented as Ac-AEDG-OH, whereas the amidated derivative additionally changes the C-terminal carboxyl group into an amide, which is Ac-AEDG-NH2. These are different chemical structures and should be distinguished based on their sequence and analytical documentation, rather than exclusively by trade names.

What Can Make One Nasal Spray Different from Another?

The chemical form, concentration, purity, pH, excipients, preservative system, viscosity, pump performance, droplet size, spray pattern, stability and dose uniformity can all be important. FDA guidelines for nasal products explicitly acknowledge that the properties of the formulation and the device jointly affect product performance.

Limitations of Evidence Regarding Nasal Spray

The most important limitation is the fact that direct research on intranasal Epitalon is almost exclusively preclinical in nature.

Rat studies are useful because they demonstrate that measurable biological responses can occur following intranasal administration of Epitalon. [1–3] However, they do not establish systemic absorption or central nervous system pharmacokinetics in humans.

Another limitation is that older experiments were not modern studies of nasal formulation development. They did not systematically characterise pump performance, spray geometry, droplet size distribution, nasal deposition site, mucociliary clearance, pharmacokinetics, or human tolerance.

Thirdly, the observed cortical neural responses do not prove a specific delivery pathway. The studies did not directly measure intact Epitalon travelling from the nasal cavity to specific brain structures.

Fourthly, commercial sprays may use formulations and devices that differ significantly from the preparations used in historical studies.

Fifthly, N-acetyl Epitalon introduces an additional evidence gap. Chemical registries confirm that this is a distinct acetylated molecule, but mere presence in a registry is not proof of nasal pharmacokinetics in humans, efficacy, safety or equivalence to AEDG.

Finally, the operation of the device itself can affect exposure. General studies of nasal products show that formulation properties and spray geometry alter the site of deposition of the material in the nose. As a result, even two chemically identical solutions should not automatically be considered equivalent if they use different pump systems.

Disclaimer

This article is for educational and scientific-informational purposes only and does not constitute medical advice, dosage guidelines, instructions for using a nasal spray, formulation instructions, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide, and direct evidence regarding the intranasal route comes mainly from animal studies rather than controlled clinical trials in humans. Human intranasal bioavailability, central nervous system exposure, route-specific safety, optimal formulation, and validated dosage have not been established. N-acetyl Epitalon and amidated derivatives are chemically modified forms and should not be assumed to have the same pharmacology or evidence base as unmodified AEDG.

References

[1] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nozdrachev, A. D. (2007). Effects of intranasal administration of Epitalon on neuron activity in the rat neocortex. Neuroscience and Behavioral Physiology, 37(9), 889–893. https://doi.org/10.1007/s11055-007-0095-3

[2] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nosdrachev, A. D. (2006). Intranasal Epitalon infusion modulates neuronal activity in the rat neocortex. Sechenov Physiological Journal of Russia, 92(8), 949–956. https://pubmed.ncbi.nlm.nih.gov/17217245/

[3] Sibarov, D. A., Nozdrachev, A. D., & Khavinson, V. K. (2002). Epitalon influences pineal secretion in stress-exposed rats in the daytime. Neuro Endocrinology Letters, 23(5–6), 452–454. https://pubmed.ncbi.nlm.nih.gov/12500171/

[4] Foo, M. Y., Cheng, Y.-S., Su, W.-C., & Donovan, M. D. (2007). The influence of spray properties on intranasal deposition. Journal of Aerosol Medicine, 20(4), 495–508. https://doi.org/10.1089/jam.2007.0638

[5] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691

[6] U.S. Food and Drug Administration. (2002). Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation: Guidance for Industry.

[7] U.S. Food and Drug Administration. (2003). Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action: Draft Guidance for Industry.

[8] National Center for Biotechnology Information. (2026). PubChem Compound Summary for CID 171390141, N-Acetyl Epitalon.

[9] U.S. Food and Drug Administration. (2026). Global Substance Registration System: N-Acetyl Epitalon, UNII UXR7AF6R4F.